Compare BioNano Genomics Inc (BNGO) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs S&P Global Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while S&P Global Inc trades at $408.41 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 8819.9× BioNano Genomics Inc's market cap, and S&P Global Inc pays a 0.95% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SPGI | |
|---|---|---|
Market Cap | $13.66M | $120.48B |
Sector | Health | Financials |
52-Week High | $4.92 | $534.79 |
52-Week Low | $1.06 | $370.42 |
Enterprise Value | $16.26M | $131.97B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
S&P Global (SPGI) trades at $409.55, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $4.83, beating estimates, with revenue growth accelerating to $15.34B in 2025. Analyst consensus remains strongly bullish with 85.7% buy ratings and a $523.20 price target, representing 28% upside potential from current levels.
SPGI presents a compelling investment case with robust profitability (30.5% net margin) and strategic AI partnerships, though technical indicators suggest near-term pressure. The key risk involves maintaining premium valuations (P/E 24.9) amid economic uncertainty, while institutional confidence remains high with aggressive buyback programs supporting shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
